Irinotecan is a topoisomerase inhibitor, widely used in treatment of malignancies including
pancreatic ductal adenocarcinoma (PDAC) as part of the FOLFIRINOX regimen prescribed …

The prognosis of patients with pancreatic cancer continues to remain dismal, even though
numerous trials have been conducted to establish more effective therapies in Japan and …

Background We evaluated the efficacy and safety of a modified FOLFIRINOX regimen for
chemotherapy-naïve patients with metastatic pancreatic cancer. Methods Patients with …

Purpose Efficacy and safety of nab-paclitaxel plus gemcitabine have not been clarified in
Japanese patients with metastatic pancreatic cancer. No pharmacokinetic profile of co …

Drug combination therapies for cancer treatment show high efficacy but often induce severe
side effects, resulting in dose or cycle number reduction. We investigated the impact of …

Background Irinotecan, oxaliplatin and leucovorin-modulated fluorouracil (FOLFIRINOX)
and the combination regimen of gemcitabine and nanoparticle albumin-bound paclitaxel …

Aim We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and
oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally …

Background There is no established second-line treatment after failure of gemcitabine plus
nab-paclitaxel (GnP) therapy for metastatic pancreatic cancer (MPC). The purpose of this …

BACKGROUND FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem+ nabPTX) were
recently introduced for metastatic pancreatic cancer treatment. However, studies that …

Abstract Background/Purpose We evaluated efficacy of neoadjuvant therapy with
gemcitabine and nab‐paclitaxel (GNP‐NAT) in borderline resectable pancreatic cancer (BR …